ReviewInternational journal of clinical and experimental pathology2012
ALK-immunoreactive neoplasms.
Review in International journal of clinical and experimental pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Inflammatory myofibroblastic tumor of omentum mimicking an ovarian lesion: A case report.Radiology case reports · 2026Article
- ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression.Journal of hematopathology · 2024Article
- Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.Discover oncology · 2024Review
- Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report.Diagnostic pathology · 2023Article
- Endotracheal inflammatory myofibroblastic tumour: A rare cause of central airway occlusion in adults.Respirology case reports · 2022Article
- Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.Journal of cancer research and clinical oncology · 2022Article
- Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma HarboringFrontiers in oncology · 2022Article
- Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.European journal of haematology · 2021Article
- Cancer Stem-Like Cells in a Case of an Inflammatory Myofibroblastic Tumor of the Lung.Frontiers in oncology · 2020Article
- Review
- Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.RSC advances · 2018Review
- Detection of ALK rearrangements in lung cancer patients using a homebrew PCR assay.Oncotarget · 2017Article
- Article
- Unveiling Cancer.Sultan Qaboos University medical journal · 2015Article
- Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors.Cell death & disease · 2015Article
- Increased ALK1 copy number and renal cell carcinoma-a case report.Virchows Archiv : an international journal of pathology · 2014Article
- Review
- Anaplastic large cell lymphoma ALK-negative clinically mimicking alcoholic hepatitis - a review.Autopsy & case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextSince the first discovery of anaplastic lymphoma kinase (ALK) in anaplastic large cell lymphoma (ALCL) by Morris et al in 1994, the number of ALK-positive neoplasms, either in the form of translocation or gain-of-function mutations, have been dramatically expanded from ALCL of T- and NK-cell origin, to diffuse large B-cell lymphoma, inflammatory myofibroblastic tumor (IMT), neuroblastoma, non-small cell lung carcinoma (NSCLC), undifferentiated anaplastic thyroid carcinoma, and rare type of sarcomas.
objectiveThis review covers the major aspects of ALK-immunoreactive neoplasms with emphasis on the pathogenesis of ALK-positive neoplasms. The new advances and rapid-evolving practices using ALK inhibitors for therapy are also discussed at the end of this review. DATA SOURCES: ALK(+) articles published in English literature are retrieved and critically reviewed.
conclusionALK(+) neoplasia is a rapidly growing field and the list of ALK(+) neoplasms is being expanded continuously. Accurate and correct diagnosis of ALK(+) neoplasms is of paramount importance in guiding the appropriate treatment in the era of personalized medicine using specific ALK inhibitor.
Indexed as
Identifiers
22808292PMC3396068W59923497What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.